Skip to main content
SpringerLink
Log in

Burden of illness low in Japanese CLL patients

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 Japanese Yen

Reference

  • Mahlich J, et al. Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib. PharmacoEconomics-Open : 27 Apr 2017. Available from: URL: http://dx.doi.org/10.1007/s41669-017-0024-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burden of illness low in Japanese CLL patients. PharmacoEcon Outcomes News 777, 8 (2017). https://doi.org/10.1007/s40274-017-3947-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3947-2

Search

Navigation